PA8432301A1 - Analogos de indazol sustituido. - Google Patents
Analogos de indazol sustituido.Info
- Publication number
- PA8432301A1 PA8432301A1 PA19978432301A PA8432301A PA8432301A1 PA 8432301 A1 PA8432301 A1 PA 8432301A1 PA 19978432301 A PA19978432301 A PA 19978432301A PA 8432301 A PA8432301 A PA 8432301A PA 8432301 A1 PA8432301 A1 PA 8432301A1
- Authority
- PA
- Panama
- Prior art keywords
- indazole
- analogs
- replaced
- acceptable salts
- pde
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
ESTA INVENCION SE REFIERE A COMPUESTOS DE FORMULA 1 Y SALES FARMACEUTICAMENTE ACEPTABLES DE LOS MISMOS, EN LOS QUE R, R1 Y R2 SON TAL COMO SE DEFINE EN LA PRESENTE. LA INVENCION ESTA ADEMAS RELACIONADA CON COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN, Y O SALES ACEPTABLES DE LOS MISMOS, PARA LA INHIBICION DE LA FOSFODIESTERASA (PDE) TIPO IV O DE LA PRODUCCION DE FACTOR DE NECROSIS TUMORAL (TNF) EN UN MAMIFERO.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2038596P | 1996-06-25 | 1996-06-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PA8432301A1 true PA8432301A1 (es) | 1999-12-27 |
Family
ID=21798354
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PA19978432301A PA8432301A1 (es) | 1996-06-25 | 1997-06-10 | Analogos de indazol sustituido. |
Country Status (43)
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997048697A1 (en) | 1996-06-19 | 1997-12-24 | Rhone-Poulenc Rorer Limited | Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase |
| YU11299A (sh) * | 1996-09-04 | 2001-07-10 | Pfizer Inc. | Derivati indazola |
| US6248746B1 (en) | 1998-01-07 | 2001-06-19 | Euro-Celtique S.A. | 3-(arylalkyl) xanthines |
| CA2309175A1 (en) * | 1997-11-04 | 1999-05-14 | Pfizer Products Inc. | Therapeutically active compounds based on indazole bioisostere replacement of catechol in pde4 inhibitors |
| ATE290002T1 (de) * | 1999-12-23 | 2005-03-15 | Icos Corp | Cyclische amp spezifische phosphodiesterase inhibitoren |
| US6362213B1 (en) | 1999-12-23 | 2002-03-26 | Icos Corporation | Cyclic AMP-specific phosphodiesterase inhibitors |
| US6953774B2 (en) | 2000-08-11 | 2005-10-11 | Applied Research Systems Ars Holding N.V. | Methods of inducing ovulation |
| US7205320B2 (en) | 2001-01-22 | 2007-04-17 | Memory Pharmaceuticals Corp. | Phosphodiesterase 4 inhibitors |
| US7153871B2 (en) | 2001-01-22 | 2006-12-26 | Memory Pharmaceuticals Corporation | Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs |
| US6982274B2 (en) * | 2001-04-16 | 2006-01-03 | Eisai Co., Ltd. | 1H-indazole compound |
| PT1908463E (pt) | 2001-12-14 | 2011-12-19 | Merck Serono Sa | Método para induzir a ovulação utilizando um modulador de nível camp não polipeptídico |
| BR0313000A (pt) | 2002-07-19 | 2005-07-12 | Memory Pharm Corp | Compostos, composição farmacêutica e método para efetuar a inibição da enzima pde4, realçar a cognição e/ou tratar a psicose em um paciente |
| NZ537724A (en) | 2002-07-19 | 2006-10-27 | Memory Pharm Corp | Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs |
| BR0315705A (pt) * | 2002-11-19 | 2005-09-06 | Memory Pharm Corp | Inibidores de fosfodiesterase-4 |
| WO2004094411A1 (en) * | 2003-04-18 | 2004-11-04 | Memory Pharmaceuticals Corporation | Pyrazole derivatives as phosphodiesterase 4 inhibitors |
| US20090048255A1 (en) * | 2003-07-21 | 2009-02-19 | Schumacher Richard A | Phosphodiesterase 4 inhibitors, including n-substituted aniline and diphenylamine analogs |
| MY141255A (en) * | 2003-12-11 | 2010-03-31 | Memory Pharm Corp | Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs |
| WO2006044528A1 (en) * | 2004-10-15 | 2006-04-27 | Memory Pharmaceuticals Corporation | Pyrazole derivatives as phosphodiesterase 4 inhibitors |
| US7601847B2 (en) | 2004-10-26 | 2009-10-13 | Wyeth | Preparation and purification of 4-(indazol-3-yl)phenols |
| WO2006129158A2 (en) * | 2005-05-30 | 2006-12-07 | Ranbaxy Laboratories Limited | 3 - indazolyl - isoxazoline derivatives as inhibitors of phosphodiesterase type - i |
| EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
| JP2009506069A (ja) | 2005-08-26 | 2009-02-12 | ブレインセルス，インコーポレイティド | ムスカリン性受容体調節による神経発生 |
| US7781460B2 (en) | 2005-09-05 | 2010-08-24 | Ranbaxy Laboratories Limited | Substituted indazoles as inhibitors of phosphodiesterase type-IV |
| WO2007031838A1 (en) | 2005-09-16 | 2007-03-22 | Ranbaxy Laboratories Limited | Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors |
| CA2625153A1 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| US20070112017A1 (en) | 2005-10-31 | 2007-05-17 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| EP2377531A2 (en) | 2006-05-09 | 2011-10-19 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| MX2009009793A (es) | 2007-03-14 | 2009-10-16 | Ranbaxy Lab Ltd | Derivados de pirazolo (3,4-b) piridina como inhibidores de fosfodiesterasa. |
| US20100029689A1 (en) * | 2008-07-02 | 2010-02-04 | Memory Pharmaceuticals Corporation | Phosphodiesterase 4 inhibitors |
| US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| NZ599597A (en) * | 2009-10-30 | 2013-05-31 | Janssen Pharmaceutica Nv | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS |
| WO2013106547A1 (en) | 2012-01-10 | 2013-07-18 | President And Fellows Of Harvard College | Beta-cell replication promoting compounds and methods of their use |
| US20150125438A1 (en) * | 2012-07-20 | 2015-05-07 | Sang Jae Kim | Anti-Inflammatory Peptides and Composition Comprising the Same |
| WO2015166370A1 (en) | 2014-04-28 | 2015-11-05 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine d1 ligands |
| KR20220167441A (ko) * | 2021-06-11 | 2022-12-21 | 주식회사 메타센테라퓨틱스 | 신규한 인돌 유도체 및 이의 최종당화산물 관련 질환의 치료 용도 |
| KR20220167804A (ko) * | 2021-06-11 | 2022-12-22 | 주식회사 메타센테라퓨틱스 | 인돌 유도체를 포함하는 최종당화산물 관련 질환의 치료용 조성물 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB753573A (en) * | 1953-06-17 | 1956-07-25 | Ici Ltd | New dyestuffs intermediates |
| GB8707051D0 (en) * | 1986-04-15 | 1987-04-29 | Ici America Inc | Heterocyclic carboxamides |
| PT100441A (pt) * | 1991-05-02 | 1993-09-30 | Smithkline Beecham Corp | Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso |
| TW223004B (es) * | 1991-11-25 | 1994-05-01 | Sumitomo Chemical Co | |
| US5444038A (en) * | 1992-03-09 | 1995-08-22 | Zeneca Limited | Arylindazoles and their use as herbicides |
| AU677776B2 (en) * | 1992-04-02 | 1997-05-08 | Smithkline Beecham Corporation | Compounds useful for treating allergic and inflammatory diseases |
| US5612360A (en) * | 1992-06-03 | 1997-03-18 | Eli Lilly And Company | Angiotensin II antagonists |
| US5554620A (en) * | 1993-09-14 | 1996-09-10 | Sterling Winthrop Inc. | Substituted 6,11-ethano-6,11-dihydrobenzo[b] quinolizinium salts and compositions and methods of use thereof |
| JPH07215952A (ja) * | 1993-12-06 | 1995-08-15 | Otsuka Pharmaceut Factory Inc | カテコール誘導体 |
| WO1996012720A1 (en) * | 1994-10-20 | 1996-05-02 | Pfizer Inc. | Bicyclic tetrahydro pyrazolopyridines and their use as medicaments |
-
1997
- 1997-06-02 TR TR1998/02685T patent/TR199802685T2/xx unknown
- 1997-06-02 KR KR1019980710961A patent/KR20000022516A/ko active IP Right Grant
- 1997-06-02 IL IL12703697A patent/IL127036A/en not_active IP Right Cessation
- 1997-06-02 DE DE69723447T patent/DE69723447T2/de not_active Expired - Fee Related
- 1997-06-02 EP EP97921992A patent/EP0912558B1/en not_active Expired - Lifetime
- 1997-06-02 CN CN97195846A patent/CN1080260C/zh not_active Expired - Fee Related
- 1997-06-02 SK SK1765-98A patent/SK176598A3/sk unknown
- 1997-06-02 CZ CZ984233A patent/CZ423398A3/cs unknown
- 1997-06-02 HU HU9903009A patent/HUP9903009A3/hu unknown
- 1997-06-02 PL PL97330974A patent/PL330974A1/xx unknown
- 1997-06-02 DK DK97921992T patent/DK0912558T3/da active
- 1997-06-02 ES ES97921992T patent/ES2201299T3/es not_active Expired - Lifetime
- 1997-06-02 SI SI9730553T patent/SI0912558T1/xx unknown
- 1997-06-02 EA EA199801047A patent/EA002274B1/ru not_active IP Right Cessation
- 1997-06-02 WO PCT/IB1997/000630 patent/WO1997049702A1/en not_active Application Discontinuation
- 1997-06-02 AT AT97921992T patent/ATE244713T1/de not_active IP Right Cessation
- 1997-06-02 JP JP50258998A patent/JP3152940B2/ja not_active Expired - Fee Related
- 1997-06-02 AU AU27857/97A patent/AU716376B2/en not_active Ceased
- 1997-06-02 BR BR9712782-5A patent/BR9712782A/pt not_active Application Discontinuation
- 1997-06-02 CA CA002258285A patent/CA2258285C/en not_active Expired - Fee Related
- 1997-06-02 PT PT97921992T patent/PT912558E/pt unknown
- 1997-06-05 HN HN1997000079A patent/HN1997000079A/es unknown
- 1997-06-05 US US08/869,358 patent/US6040329A/en not_active Expired - Fee Related
- 1997-06-10 PA PA19978432301A patent/PA8432301A1/es unknown
- 1997-06-12 GT GT199700075A patent/GT199700075A/es unknown
- 1997-06-19 AP APAP/P/1997/001020A patent/AP1025A/en active
- 1997-06-20 TW TW086108723A patent/TW434237B/zh not_active IP Right Cessation
- 1997-06-23 MY MYPI97002820A patent/MY116915A/en unknown
- 1997-06-23 AR ARP970102755A patent/AR007456A1/es unknown
- 1997-06-24 ZA ZA975581A patent/ZA975581B/xx unknown
- 1997-06-24 DZ DZ970104A patent/DZ2254A1/fr active
- 1997-06-24 ID IDP972170A patent/ID18579A/id unknown
- 1997-06-24 TN TNTNSN97108A patent/TNSN97108A1/fr unknown
- 1997-06-25 MA MA24679A patent/MA24225A1/fr unknown
- 1997-06-25 HR HR970350A patent/HRP970350B1/xx not_active Application Discontinuation
- 1997-06-25 CO CO97035540A patent/CO4900056A1/es unknown
-
1998
- 1998-11-27 IS IS4910A patent/IS4910A/is unknown
- 1998-12-11 OA OA9800235A patent/OA10934A/en unknown
- 1998-12-23 NZ NZ332752A patent/NZ332752A/en unknown
- 1998-12-23 NO NO986103A patent/NO986103D0/no not_active Application Discontinuation
- 1998-12-24 YU YU60198A patent/YU60198A/sh unknown
-
1999
- 1999-01-07 BG BG103056A patent/BG64052B1/bg unknown
- 1999-08-31 HK HK99103733A patent/HK1018700A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PA8432301A1 (es) | Analogos de indazol sustituido. | |
| PA8437301A1 (es) | Derivados de indazol | |
| CO4650038A1 (es) | Derivados del indazol sustituidos y compuestos relacionados | |
| ES2196377T3 (es) | Derivados de naftiridina. | |
| AR027437A1 (es) | Derivados de purina | |
| PA8547901A1 (es) | Derivados de 4-piperacinilindol con afinidad receptora de 5-ht6 | |
| UY26968A1 (es) | Agentes terapéuticos | |
| GT200100137A (es) | Pro-drogas de derivados de 4-fenil-piridina. | |
| AR028810A1 (es) | Derivados de arilpiperazinil-ciclohexil indol, composiciones farmaceuticas que los comprenden y el uso de los mismos para la manufactura de medicamentos para el tratamiento de la depresion | |
| ES2094721T3 (es) | Analogos de la camptotecina solubles en agua. | |
| MXPA05011296A (es) | Conjugados de fosfonato inhibidores de la cinasa. | |
| AR028985A1 (es) | Compuestos derivados de quinolin-2-ona- sustituidos con heteroarilo utiles como agentes anticancerigenos, procedimiento de tratamiento de enfermedades utilizando dicho compuesto, composicion farmaceutica que lo contiene | |
| PA8575401A1 (es) | Derivados de heteroarilamida benzocondensada de tienopiridinas utiles como agentes terapeuticos, composiciones farmaceuticas que incluyen a los mismos y metrodos para su uso | |
| CR8171A (es) | Derivados de pirrolo[3,4-c] pyrazol activos como inhibidores de quinasa | |
| ES2171884T3 (es) | Compuestos de quinazolina. | |
| AR029216A1 (es) | Compuestos inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias; composicion farmaceutica y procedimiento de tratamiento | |
| DE69827236D1 (en) | Matrix-metalloproteinase-hemmer | |
| ECSP066349A (es) | Inhibidores de transferasa de proteína de farnesilo novedosos como agentes antitumorales | |
| CL2004000965A1 (es) | Compuestos derivados de 2h-pirazol-3-il de formula definida, que actuan como inhibidores de quinasa p38 y tnf; composicion farmaceutica que comprende a uno de los compuestos; uso de la composicion en la preparacion de un medicamento; y uso de los com | |
| ECSP034602A (es) | Derivados sustituidos 2-fenilaminoimidazolina fenil cetona como antagonistas ip | |
| CR7612A (es) | Compuestos de fenilsulfonamida sustituida inhibidores de la produccion de beta-amiloide | |
| ATE211740T1 (de) | Substituierte indazolderivate | |
| MX9306311A (es) | Compuestos antagonistas del receptor de 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que los contienen | |
| TWI268280B (en) | Novel farnesyl protein transferase inhibitors as antitumor agents | |
| SV1997000033A (es) | Derivados de acido 4-arilbutirico sustituido como inhibisor de matriz de metaloproteasa |